Investment Thesis
BioCardia faces imminent insolvency risk with zero revenue, -$8.3M operating losses, and only ~4 months of cash runway at current -$7.4M annual burn rate. The company's minimal equity base ($895K) and weak current ratio (1.12x) leave no margin for error. Without immediate revenue generation, capital injection, or acquisition, the company is on a trajectory toward default.
Strengths
- No long-term debt burden limits financial obligations
- Positive cash position of $2.5M provides short-term runway
- Recent insider Form 4 activity may indicate management confidence in turnaround
Risks
- Complete revenue collapse: $0 revenue with -100% YoY decline indicates failed commercialization or product shutdown
- Critical cash burn: -$7.4M operating cash burn with only $2.5M cash equals ~4-month survival window
- Minimal equity cushion: Stockholders equity of $895K provides insufficient buffer for operational challenges or asset impairment
- Weak liquidity position: Current ratio of 1.12x below comfort threshold; total assets only $3.4M indicate resource constraints
- Absence of profitable operations: -$8.2M net loss with negative ROE (-919%) and ROA (-241%) demonstrate severe value destruction
Key Metrics to Watch
- Monthly cash burn rate and remaining cash runway (survival critical)
- Revenue generation or product commercialization progress (existence of viable revenue path)
- Capital raise announcements, M&A activity, or strategic partnership developments
Financial Metrics
Revenue
0.0
Net Income
-8.2M
EPS (Diluted)
$0.00
Free Cash Flow
-7.4M
Total Assets
3.4M
Cash
2.5M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-919.3%
ROA
-241.1%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
1.12x
Quick Ratio
1.12x
Debt/Equity
0.00x
Debt/Assets
73.8%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T08:46:19.688505 |
Data as of: 2025-12-31 |
Powered by Claude AI